Drug intelligence / Profile preview

AFNT-313

Development stage: Preclinical
Lead developer: Affini-T Therapeutics
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

AFNT-313 is an investigational autologous T cell receptor (TCR)-T cell therapy being developed by Affini-T Therapeutics. It is designed to target the P53 R175H mutation, a common oncogenic driver in various solid tumors. The therapy utilizes Affini-T's proprietary THRIVE and TUNE platforms to engineer T cells with enhanced specificity and function against tumor cells harboring the P53 R175H mutation. The mechanism of action involves inhibition of p53, aiming to restore immune recognition and destruction of cancer cells with this specific mutation. As of now, AFNT-313 is in preclinical development[1][3][4].

Targets

p53 R175H/HLA-A*02:01 (Tumor protein p53 R175H mutant peptide-HLA-A*02:01 complex)

Beyond the preview

Go deeper on AFNT-313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AFNT-313.

Explore the full profile